Genetic Variants Modulating Response to Celecoxib Chemoprevention in Oral Leukoplakia: Correlation with Histopathological Grading in Pakistani Patients
DOI:
https://doi.org/10.63682/jns.v13i1.9319Keywords:
Celecoxib, Chemoprevention, Genetic variants, Oral leukoplakia, Pakistani populationAbstract
Background: The risk of developing oral squamous cell carcinoma varies for oral leukoplakia, a common premalignant lesion. Cyclooxygenase-2 (COX-2) inhibitors, like celecoxib, have demonstrated promise in chemoprevention; however, inter-individual variability in treatment response is still a significant obstacle. Celecoxib sensitivity may be impacted by genetic variations in drug metabolism and inflammation-related pathways.
Objective: The purpose of this study was to evaluate associations with lesion grading and examine the relationship between specific genetic variants and the clinical and histopathological response to celecoxib chemoprevention in patients with oral leukoplakia from Pakistan.
Methods: Celecoxib was administered to a group of Pakistani patients with oral leukoplakia for a predetermined amount of time. Biopsies taken before and after treatment were analyzed for histopathological grading, and standardized criteria were used to measure clinical regression. Candidate variants in COX-2 and associated pathways (such as prostaglandin synthesis and xenobiotic metabolism) were genotyped. Using the proper statistical models, relationships between genotypes, histopathological response, and clinical outcomes were examined.
Results: Distinct genetic variants demonstrated significant associations with response to celecoxib. Patients carrying specific alleles exhibited greater histopathological regression and down-grading of dysplasia compared to non-carriers. Conversely, certain polymorphisms were linked with limited or no improvement, highlighting genetic heterogeneity in treatment outcomes. The correlation between genotype and histological grading provided mechanistic insights into celecoxib’s chemo preventive efficacy.
Conclusion: This study identifies genetic variants that modulate the response to celecoxib chemoprevention in oral leukoplakia among Pakistani patients. Incorporating genetic profiling may enable personalized chemo preventive strategies, improving risk stratification and treatment outcomes in premalignant oral lesions. Larger studies are warranted to validate these findings and guide precision medicine approaches in oral cancer prevention
Downloads
References
Warnakulasuriya S. Oral potentially malignant disorders: A comprehensive review on clinical aspects and management. Oral oncology. 2020 Mar 1;102:104550. http://doi:10.1016/j.oraloncology.2019.104550. Epub 2020 Jan 22. PMID: 31981993.
Naushin T, Iqbal Z, Khan AS, Mehmood U, Khan T, Mahmood S, Hassan MU, Mahmood M, Hassan TU. Oral Leukoplakia: An Overview of Histopathological Spectrum Focusing On WHO Grading System and Binary System of Oral Epithelial Dysplasia: Oral Leukoplakia: Histopathological Spectrum Focusing On Oral Epithelial Dysplasia. Pakistan Journal of Health Sciences. 2025 Jan 31:348-52.
Liao YH, Chou WY, Chang CW, Lin MC, Wang CP, Lou PJ, Chen TC. Chemoprevention of oral cancer: A review and future perspectives. Head & neck. 2023 Apr;45(4):1045-59. http://doi:10.1002/hed.27301. Epub 2023 Feb 21. PMID: 36810813.
Rodrigues P, Bangali H, Hammoud A, Mustafa YF, Al-Hetty HR, Alkhafaji AT, Deorari MM, Al-Taee MM, Zabibah RS, Alsalamy A. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers. Medical oncology. 2024 Jan 2;41(1):41. http://doi:10.1007/s12032-023-02256-7. PMID: 38165473.
Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase‐2 in cancer: a review. Journal of cellular physiology. 2019 May;234(5):5683-99. http://doi:10.1002/jcp.27411. Epub 2018 Oct 20. PMID: 30341914.
Wen B, Wei YT, Mu LL, Wen GR, Zhao K. The molecular mechanisms of celecoxib in tumor development. Medicine. 2020 Oct 2;99(40):e22544. http://doi:10.1097/MD.0000000000022544. PMID: 33019464; PMCID: PMC7535670.
Lee SJ, Park MK, Shin DS, Chun MH. Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism. Drug design, development and therapy. 2017 Sep 13:2727-36. http://doi:10.2147/DDDT.S143807. PMID:29066864; PMCID: PMC5604555
Hijos-Mallada G, Sostres C, Gomollón F. NSAIDs, gastrointestinal toxicity and inflammatory bowel disease. Gastroenterología y Hepatología (English Edition). 2022 Mar 1;45(3):215-22. http://doi:10.1016/j.gastrohep.2021.06.003. Epub 2021 Jun 19. PMID: 34157367.
Iamaroon A. Targeted Therapy of Oral Cancer: a Focus on COX-2 Inhibitors. J Dent Assoc Thai. 2016 Jan;66(1).
Chiang SL, Velmurugan BK, Chung CM, Lin SH, Wang ZH, Hua CH, Tsai MH, Kuo TM, Yeh KT, Chang PY, Yang YH. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Scientific reports. 2017 Jul 24;7(1):6235. http://doi:10.1038/s41598-017-06673-3. PMID: 28740192; PMCID: PMC5524966.
Strube W, Aksar A, Bauer I, Barbosa S, Benros M, Blankenstein C, Campana M, Davidovic L, Glaichenhaus N, Falkai P, Görlitz T. Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial. Journal of Neural Transmission. 2023 Aug;130(8):1039-48. http://doi:10.1007/s00702-022-02566-6. Epub 2022 Nov 19. PMID: 36401749; PMCID: PMC10374797.
Leng WD, Wen XJ, Kwong JS, Huang W, Chen JG, Zeng XT. COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data. BMC cancer. 2016 Jul 13;16(1):457. http://doi:10.1186/s12885-016-2535-3. PMID: 27412115; PMCID: PMC4942952.
Li Q, Ma C, Zhang Z, Chen S, Zhi W, Zhang L, Zhang G, Shi L, Cao F, Ma T. Association between cyclooxygenase-2 (COX-2) 8473 T> C polymorphism and cancer risk: a meta-analysis and trial sequential analysis. BMC cancer. 2018 Aug 24;18(1):847. http://doi:10.1186/s12885-018-4753-3. PMID: 30143023; PMCID: PMC6109290.
De Andrade RS, Abrão SM, Poli-Frederico RC. O Impacto do Polimorfismo rs20417 do Gene COX-2 no Câncer Oral. Ensaios e Ciência: Ciências Biológicas, Agrárias e da Saúde. 2024 Nov 27;28(4):502-5.
da Silveira MM, Melo LD, Gomes FM, Andrade LJ, Serur IP, Piscoya IC, Gueiros RM, Palmeira do Ó K, de Lima RE, Brasileiro VA, Vasconcelos LR. Polymorphisms of CYP2C9* 2, CYP2C9* 3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. The application of clinical genetics. 2019 Aug 2:151-9. http://doi:10.2147/TACG.S197316. PMID: 31447576; PMCID: PMC6684853.
Mhandire DZ, Goey AK. The value of pharmacogenetics to reduce drug-related toxicity in cancer patients. Molecular diagnosis & therapy. 2022 Mar;26(2):137-51. http://doi:10.1007/s40291-021-00575-x. Epub 2022 Feb 3. PMID: 35113367; PMCID: PMC8975257.
Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JA, Grosser T. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti‐inflammatory drugs. Clinical Pharmacology & Therapeutics. 2020 Aug;108(2):191-200. http://doi:10.1007/s40291-021-00575-x. Epub 2022 Feb 3. PMID: 35113367; PMCID: PMC8975257.
Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. Journal of Oral Pathology & Medicine. 2016 Mar;45(3):155-66. http://doi:10.1111/jop.12339. Epub 2015 Jul 20. PMID: 26189354.
Khokhar MA. " The poor have no memories"-Oral histories of women with oral cancer in Pakistan (Doctoral dissertation, University of Sheffield).
Loomans-Kropp HA, Umar A. Cancer prevention and screening: the next step in the era of precision medicine. NPJ precision oncology. 2019 Jan 28;3(1):3. http://doi:10.1038/s41698-018-0075-9. PMID: 30701196; PMCID: PMC6349901.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
